Nature Biotechnology reviews the state of play of senolytics
Nature Biotechnology - 12-Nov-2020In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...
Eternans
Biotechnology company developing senolytic agents
We are a UK based biotech startup, developing senolytic agents for the treatment of senescence-associated diseases and disorders by selectively killing senescent cells.
Dissolved on 17-October-2023
Details last updated 20-Nov-2020
Eternans News
Topics mentioned on this page:
Senescent Cells
